A23V2250/5116

SPECIALIZED FLOUR FOR NUTRITION MEALS FOR DIABETES AND PREPARATION METHOD AND USE THEREOF
20170224001 · 2017-08-10 ·

Disclosed are specialized flour for nutrition meals for diabetes and a preparation method and use thereof. The flour is based on cereal meal as a basic material and is added to a defatted soybean vegetable protein powder and a soybean tissue isolated dietary fiber power, wherein in the dry flour base, the content of protein is 20-26 weight %, the content of the dietary fiber is 4-10 weight %, the content of carbohydrate is no more than 65 weight %, and the content of fat is no more than 4% of the weight. The method comprises physically mixing the cereal meal, the defatted soybean vegetable protein powder and the soybean tissue isolated dietary fiber power under atmospheric pressure. Food and semi-finished products made from the flour are used for preventing and/or treating diabetes.

METHOD FOR PRODUCING A READY-TO-USE, LONG-LIFE INFANT MILK
20170215467 · 2017-08-03 ·

The invention relates to a method for producing a milk food made as a substitute for breast milk, in the form of a ready-to-use, long-life liquid. The invention also relates to the facility for implementing said method and to the milk food made as a substitute for breast milk produced by said method.

Dietary fiber for treating patients suffering from methylmalonic acidemia and propionic acidemia
20220040211 · 2022-02-10 · ·

The present invention concerns a composition comprising dietary fiber for use in the dietary management of methylmalonic acidemia (MMA) and/or propionic acidemia (PA), and/or for use in treating and/or reducing MMA and/or PA, and/or treating, reducing and/or preventing symptoms associated therewith.

Dietary fiber for treating patients suffering from methylmalonic acidemia and propionic acidemia
20220040211 · 2022-02-10 · ·

The present invention concerns a composition comprising dietary fiber for use in the dietary management of methylmalonic acidemia (MMA) and/or propionic acidemia (PA), and/or for use in treating and/or reducing MMA and/or PA, and/or treating, reducing and/or preventing symptoms associated therewith.

2'-fucosyllactose for the prevention and treatment of coronavirus-induced inflammation

The invention provides compositions and methods for utilizing oligosaccharides, such as isolated human milk oligosaccharides, to attenuate a respiratory pathogen infection-induced host inflammation and/or to promote recovery from a respiratory pathogen infection-induced host inflammation in a subject.

2'-fucosyllactose for the prevention and treatment of coronavirus-induced inflammation

The invention provides compositions and methods for utilizing oligosaccharides, such as isolated human milk oligosaccharides, to attenuate a respiratory pathogen infection-induced host inflammation and/or to promote recovery from a respiratory pathogen infection-induced host inflammation in a subject.

2'-FUCOSYLLACTOSE FOR THE PREVENTION AND TREATMENT OF CORONAVIRUS-INDUCED INFLAMMATION
20210353653 · 2021-11-18 ·

The invention provides compositions and methods for utilizing oligosaccharides, such as isolated human milk oligosaccharides, to attenuate a respiratory pathogen infection-induced host inflammation and/or to promote recovery from a respiratory pathogen infection-induced host inflammation in a subject.

2'-FUCOSYLLACTOSE FOR THE PREVENTION AND TREATMENT OF CORONAVIRUS-INDUCED INFLAMMATION
20210353653 · 2021-11-18 ·

The invention provides compositions and methods for utilizing oligosaccharides, such as isolated human milk oligosaccharides, to attenuate a respiratory pathogen infection-induced host inflammation and/or to promote recovery from a respiratory pathogen infection-induced host inflammation in a subject.

Human gastrointestinal microbiome modulating composition and methods of use

A formulation to increase the ratio of gastrointestinal microbiota in phylum Bacteroidetes to microbiota of Firmicutes phylum preferably includes about 20-60 mg/kg of body weight of fermentable fiber, about 10-30 mg/kg of body weight of beta glucan and about 20-60 mg/kg of body weight of blueberry extracts or any fruit or berry ingredient preparation containing similar phenolics. This formulation is preferably used to control body weight, body composition, and blood glucose regulation, preferably in humans, and is preferably administered orally, preferably twice per day.

Human gastrointestinal microbiome modulating composition and methods of use

A formulation to increase the ratio of gastrointestinal microbiota in phylum Bacteroidetes to microbiota of Firmicutes phylum preferably includes about 20-60 mg/kg of body weight of fermentable fiber, about 10-30 mg/kg of body weight of beta glucan and about 20-60 mg/kg of body weight of blueberry extracts or any fruit or berry ingredient preparation containing similar phenolics. This formulation is preferably used to control body weight, body composition, and blood glucose regulation, preferably in humans, and is preferably administered orally, preferably twice per day.